Evaluation of the anticancer activities of two fungal polycyclic ethanones, alternethanoxins a and b, and two of their derivatives

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 227-232

  Bury, Marina ^a   Punzo, Biancavaleria ^c   Berestetskiy, Alexander ^d   Lallemand, Benjamin ^a   Dubois, Jacques ^a   Lefranc, Florence ^a,b   Mathieu, Véronique ^a   Andolfi, Anna ^c   Kiss, Robert ^a   Evidente, Antonio ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d ALL RUSSIAN INSTITUTE OF PLANT PROTECTION   (Russian Federation)

Author keywords

Alternethanoxins; Fungal phytotoxins; In vitro anticancer activity; Polycyclic ethanones

Indexed keywords

ALTERNETHANOXIN A; ALTERNETHANOXIN B; ANTINEOPLASTIC AGENT; ETHANONE DERIVATIVE; PLANT TOXIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALTERNARIA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MYCOTOXINS; POLYCYCLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650851697     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000842     Document Type: Article

References (38)

1. Strobel GA: Phytotoxins. Annu Rev Biochem 51: 309-333, 1982.
2. Graniti A, Durbin RD and Ballio A: Phytotoxins and Plant Pathogenesis NATO ASI Series. Vol. 27. Springer-Verlag, Berlin, 1989.
3. Ballio A and Graniti A: Phytotoxins and their involvement in plant disease. Experientia 47: 751-826, 1991.
4. Evidente A: Bioactive metabolites from phytopathogenic fungi and bacteria. In: Recent Research Developments in Phytochemistry. Pandalai SG (ed.) Research Signpost, Trivandrum, pp255-292, 1997.
5. Evidente A and Motta A: Phytotoxins from fungi, pathogenic for agrarian forestal and weedy plants. In: Bioactive Compounds from Natural Sources. Tringali C (ed.) Taylor & Francis, London, pp473-525, 2001.
6. Evidente A: New fungal metabolites, as antifungal, herbicides and insecticides for biocontrol of agrarian plant pests. In: Potential & Challenges; of the series: Comprehensive Bioactive Natural Products. Vol. 1, Gupta V (ed.) Studium Press, New Delhi, 2010.
7. Evidente A, Andolfi A and Cimmino A: The fungal phytotoxins for control Cirsium arvense and Sonchus arvensis. Pest Technol Rev (In press).
8. Evidente A, Andolfi A, Cimmino A and Abouzeid MA: Phytotoxins produced by fungi responsible of forestall plant disease. In: Sustainable Agriculture: Technology, Planning and Management. Salazar A and Rios I (eds.) Nova Science Publisher Inc., New-York (In press).
9. Evidente A: Chemical and biological characterization of toxins produced by weed pathogenic fungi as potential natural herbicides. In: Natural Products for Pest Management. ACS Symposium Series 927, Rimando AM and Duke SO (eds.) ACS Washington, pp62-75, 2006.
10. Evidente A and Abouzeid MA: Characterization of phytotoxins from phytopathogenic fungi and their potential use as herbicides. In: Integrated Crop Management. In: Handbook of Sustainable Weed Management, Singh HP, Batish DR and Kholi RK (eds.) The Haworth Press Inc., New-York, pp507-514, 2006.
11. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R and Schulman CC: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77: 144-149, 1996.
12. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R and van Damme M: In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 21: 417-425, 2002.
13. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, van Vynckt F, Mijatovic T, Lefranc F, Darro F and Kiss R: 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3- dihydro-1H-benzo[de]isoquinolin-5yl}carbamoyl)acetamide (UNBS3157), a novel non-hematotoxic naphthalimide derivative with potent anti-tumor activity. J Med Chem 50: 4122-4134, 2007. (Pubitemid 47301744)
14. Lamoral-Theys D, Andolfi A, van Goietsenoven G, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyère C, Dubois J, Mathieu V, Kornienko A, Kiss R and Evidente A: Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem 52: 6244-6256, 2009.
15. Evidente A, Punzo B, Andolfi A, Beresyetskiy A and Motta A: Alternethanoxins A and B, polycyclic ethanones by Alternaria sonchi, potential mycoherbicide for Sonchus arvensis biocontrol. J Agric Food Chem 57: 6656-6660, 2009.
16. Lefranc F, Facchini V and Kiss R: Pro-autophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12: 1395-1403, 2007.
17. +-ATPase) to combat glioblastoma cells. Neurosurgery 62: 211-222, 2008.
18. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F and Kiss R: Galectin-1 knockdown increases sensitvity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127: 2399-2410, 2007. (Pubitemid 47619747)
19. Evidente A, Andolfi A, Vurro M, Zonno MC and Motta A: Cytochalasins Z1, Z2 and Z3, three 24-oxa[14]cytochalasans produced by Pyrenophora semeniperda. Phytochemistry 60: 45-53, 2002.
20. De Hauwer C, Camby I, Darro F, Migeotte I, Decaestecker C, Verbeek C, Danguy A, Pasteels JL, Brotchi J, Salmon I, van Ham P and Kiss R: Gastrin inhibits motility, decreases cell death levels and increases proliferation in human glioblastoma cell lines. J Neurobiol 37: 373-382, 1998.
21. Delbrouck C, Doyen I, Belot N, Decaestecker C, Ghanooni R, De Lavareille A, Kaltner H, Choufani G, Danguy A, Vandenhoven G, Gabius HJ, Hassid S and Kiss R: Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest 82: 147-158, 2002.
22. Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutière F, Wauthoz N, Neven P, Ingrassia L, van Antwerpen P, Lefranc F, Gelbcke M, Pirotte B, Kraus JL, Nève J, Kornienko A, Kiss R and Dubois J: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorg Med Chem (In press).
23. Huang P-L, Won S-J, Day S-H and Lin C-N: A cytotoxic acetophenone with a novel skeleton from Cynanchum taiwanianum. Helv Chim Acta 82: 1716-1720, 1999.
24. Saidou Balde E, Andolfi A, Bruyère C, Cimmino A, Lamoral-Theys D, Vurro M, van Damme M, Altomare C, Mathieu V, Kiss R and Evidente A: Investigations of fungal secondary metabolites with potential anticancer activity. J Nat Prod (In press).
25. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, van Quaquebeke E and Kiss R: Structure-activity-relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae Isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 52: 1100-1114, 2009.
26. Mijatovic T, Mathieu V, Gaussin JF, De Neve N, Ribaucour F, van Quaquebeke E, Dumont P, Darro F and Kiss R: Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 8: 402-412, 2006.
27. Mathieu V, Pirker C, Martin De Lassalle E, Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F, Berger W and Kiss R: The sodium pumpa alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 9B: 3960-3972, 2009.
28. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R and Salmon I: Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95: 641-655, 2002.
29. Boyle P and Levin B: World Cancer Report 2008. World Health Organization. International Agency for Research on Cancer. Lyon, 2008.
30. Lefranc F, Brotchi J and Kiss R: Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 2411-2422, 2005. (Pubitemid 46218735)
31. Soengas MS and Lowe SW: Apoptosis and melanoma resistance. Oncogene 22: 3138-3151, 2003.
32. El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35: 167-174, 2009.
33. Denlinger CE, Rundall BK and Jones DR: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg 16: 28-39, 2004.
34. D'Amico TA and Harpole DH Jr: Molecular biology of esophageal cancer. Chest Surg Clin North Am 10: 451-469, 2000.
35. Savage P, Stebbing J, Bower M and Crook T: Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 6: 43-52, 2009.
36. Wilson TR, Johnston PG and Longley DB: Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9: 307-319, 2009.
37. Janmaat ML, Rodriguez JA, Jimero J, Kruyt FA and Giaccone G: Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signalling. Mol Pharmacol 68: 502-510, 2005.
38. Jimenez JC, Lopez-Macia A, Gracia C, Varon S, Carrascal M, Caba JM, Royo M, Francesch AM, Cuevas C, Giralt E and Alberico F: Structure-activity relationship of kahalalide F synthetic analogues. J Med Chem 51: 4920-4931, 2008.